ATE279179T1 - Clopidogrelbisulfathaltige tablettenzubereitung - Google Patents

Clopidogrelbisulfathaltige tablettenzubereitung

Info

Publication number
ATE279179T1
ATE279179T1 AT02257582T AT02257582T ATE279179T1 AT E279179 T1 ATE279179 T1 AT E279179T1 AT 02257582 T AT02257582 T AT 02257582T AT 02257582 T AT02257582 T AT 02257582T AT E279179 T1 ATE279179 T1 AT E279179T1
Authority
AT
Austria
Prior art keywords
clopidogrel bisulfate
preparation containing
tablet preparation
containing clopidogrel
bisulfate
Prior art date
Application number
AT02257582T
Other languages
English (en)
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4170539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE279179(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Application granted granted Critical
Publication of ATE279179T1 publication Critical patent/ATE279179T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02257582T 2001-11-09 2002-11-01 Clopidogrelbisulfathaltige tablettenzubereitung ATE279179T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2363053A CA2363053C (en) 2001-11-09 2001-11-09 Clopidogrel bisulfate tablet formulation

Publications (1)

Publication Number Publication Date
ATE279179T1 true ATE279179T1 (de) 2004-10-15

Family

ID=4170539

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02257582T ATE279179T1 (de) 2001-11-09 2002-11-01 Clopidogrelbisulfathaltige tablettenzubereitung

Country Status (6)

Country Link
US (1) US6914141B2 (de)
EP (1) EP1310245B1 (de)
AT (1) ATE279179T1 (de)
AU (1) AU2002301782B8 (de)
CA (1) CA2363053C (de)
DE (1) DE60201568T2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
GB0325603D0 (en) * 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
WO2005070464A2 (en) * 2004-01-21 2005-08-04 Biofarma Ilac Sanayi Ve Ticaret A.S. A tablet formulation of clopidogrel bisulphate
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR20070009851A (ko) * 2005-07-14 2007-01-19 씨제이 주식회사 클로피도그렐 황산수소염 함유 약학 조성물
KR20070044323A (ko) * 2005-10-24 2007-04-27 에스케이케미칼주식회사 보관안정성이 개선된 클로피도그렐 황산수소염 함유 경구용제제
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
DK1847258T4 (da) 2006-04-13 2013-04-15 Acino Pharma Ag Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1900358A1 (de) 2006-09-16 2008-03-19 Cimex Pharma AG Clopidogrel enthaltende Arzneiformulierungen
CN100400035C (zh) * 2006-10-18 2008-07-09 深圳信立泰药业股份有限公司 氯吡格雷硫酸盐的固体制剂及其制备方法
HUP0600839A3 (en) * 2006-11-14 2008-09-29 Egis Gyogyszergyar Nyrt Solid pharmaceutical composition containing polymorph i of clopidogrel hydrogensulfate and process for the preparation thereof
EP1970054A3 (de) * 2007-03-14 2009-06-03 Ranbaxy Laboratories Limited Clopidogrel-Tabletten
WO2008122994A2 (en) * 2007-04-09 2008-10-16 Usv Limited Stable pharmaceutical compositions of clopidogrel bisulfate and process of preparation thereof
HUE053158T2 (hu) 2007-04-27 2021-06-28 Cydex Pharmaceuticals Inc Clopidogrelt és szulfoalkiléter ciklodextrint tartalmazó készítmények és alkalmazási eljárások
EP2095815B1 (de) * 2008-02-26 2011-10-26 Laboratorios Lesvi, S.L. Pharmazeutische Formulierungen mit Clopidogrel
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20090264460A1 (en) * 2008-04-21 2009-10-22 Mamta Mishra Clopidogrel pharmaceutical formulations
ATE482961T1 (de) 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
CN101766573B (zh) 2010-02-05 2013-02-13 上海安必生制药技术有限公司 硫酸氢氯吡格雷固体制剂的制备工艺
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (de) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetestherapie
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102309482B (zh) * 2011-06-20 2013-04-10 海南良方医药有限公司 一种硫酸氢氯吡格雷组合物及其制备方法
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
RU2540519C2 (ru) * 2013-02-05 2015-02-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма клопидогрела
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CN106176644B (zh) * 2016-08-18 2019-05-14 成都新柯力化工科技有限公司 一种氯吡格雷硫酸盐固体片剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
CA2100836C (en) * 1993-07-19 1998-02-03 Bernard Charles Sherman PHARMACEUTICAL COMPOSITION
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
WO2000001364A1 (en) * 1998-07-01 2000-01-13 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of thieno [3,2-c] pyridine derivatives
IN191030B (de) * 2001-01-24 2003-09-13 Cadila Healthcare Ltd
CA2343949A1 (en) * 2001-04-12 2002-10-12 Bernard Charles Sherman Benazepril hydrochloride tablet formulations
US6767913B2 (en) * 2001-12-18 2004-07-27 Teva Pharmaceutical Industries Ltd. Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms
US6800759B2 (en) * 2002-08-02 2004-10-05 Teva Pharmaceutical Industries Ltd. Racemization and enantiomer separation of clopidogrel
IL166593A0 (en) * 2002-08-02 2006-01-15 Racemization and enantiomer separation of clopidogrel

Also Published As

Publication number Publication date
US20030096837A1 (en) 2003-05-22
US6914141B2 (en) 2005-07-05
AU2002301782B8 (en) 2006-08-03
AU2002301782B2 (en) 2006-06-01
EP1310245A1 (de) 2003-05-14
EP1310245B1 (de) 2004-10-13
DE60201568D1 (de) 2004-11-18
CA2363053C (en) 2011-01-25
DE60201568T2 (de) 2005-10-20
CA2363053A1 (en) 2003-05-09

Similar Documents

Publication Publication Date Title
ATE279179T1 (de) Clopidogrelbisulfathaltige tablettenzubereitung
DE60219478D1 (en) Orale gabe von 6-hydroxy-oxymorphon als analgetikum
AU2002301782A1 (en) Clopidogrel bisulfate tablet formulation
ITRM20020240A0 (it) Dispositivo di sicurezza per un robot da cucina a grande scivolo.
AP2005003371A0 (en) Medication compliance device.
IL166079A0 (en) Sustained-release tablet comprising reboxetine
MXPA03006775A (es) Formulacion farmaceutica.
EE200300055A (et) Hüdrogeeli poolt juhitav ravimi annustamisvorm
MXPA03007641A (es) Formulacion farmaceutica.
DE69528838D1 (de) Verbesserte,ibuprofen und codein enthaltende,pharmazeutische zusammensetzungen
NO20041195L (no) Tablettmater.
GB2381180B (en) Animal access system
ATE285753T1 (de) Lysin enthaltende kautablette
HK1062896A1 (en) Swallow tablet comprising paracetemol
ITRM20010369A1 (it) Tettarella o ciuccio.
ZA200403614B (en) Controlled release tablets of metformin.
HUP0303860A3 (en) A pharmaceutical tablet having a high active ingredient
DE60022689D1 (de) Pharmazeutische desinfektionsmittel, die usninsäure und ein ätherisches öl enthalten
GB0118507D0 (en) Proofers date rape drug detection
DE59909714D1 (de) Calciumhaltige Brausetablette mit einem Antihistaminikum als Wirkstoff
NL1023797A1 (nl) Farmaceutische doseringsvorm die zwangerschapsvriendelijke onderscheidingstekens draagt.
GB0112385D0 (en) Woolford emergency access intruder chain
HUP0600158A2 (en) Structure-based drug design methods for identifying d-ala-d-ala ligase inhibitors as antibacterial drugs
EP1303309A4 (de) Schnellzerfallende tablette für tiere
TW494753U (en) Device for shaping Chinese medicine tablets or pellet-shaped food

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties